fda tirzepatide shortage resolved 2025 says years-long is resolved, will give limited leeway to compounders Lilly's weight-loss drug removed from

It's Dangerous for People Who Aren't Overweight to Take Ozempic Using GLP-1 medications without meeting prescribing criteria can expose someone to unnecessary risks without meaningful benefit

Melanotan 1 vs Melanotan 2 at a Glance A side-by-side look at how Melanotan I and Melanotan II differ in how they work, how they're dosed, and where each stands legally

How do weight loss treatments work

Exclusive Research & Development 3 min read Lillys Weight Loss Blockbuster cuts Heart Failure risk by 38%, halves Hospitalizations In a Phase 3 study the US drugmaker reported that, among obese people tirzepatide reduces the risk of heart failure by 38 per cent and reduces risk of hospitalization for heart failure by 56 per cent

With retatrutide, in 2026, there is no such path

The choice between them is not arbitrary, but the reasoning differs depending on the delivery method